Recent News

• 04.27.2025 - SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
• 04.27.2025 - SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
• 04.27.2025 - SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
• 02.20.2025 - SpringWorks Therapeutics Q4 2024 Earnings Conference Call
• 02.20.2025 - SpringWorks Therapeutics Q4 2024 Earnings Conference Call
• 02.20.2025 - SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
• 02.20.2025 - SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
• 02.20.2025 - SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Recent Filings

• 04.04.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.04.2025 - DEF 14A Other definitive proxy statements
• 04.04.2025 - ARS Annual Report to Security Holders
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.20.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]